China Isotope & Radiation (HKSE:01763) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 25, 2024)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Medical Devices subindustry, China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

China Isotope & Radiation (HKSE:01763) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

China Isotope & Radiation Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Li Hongbo	2201 Interest of corporation controlled by you
Lianwen Ltd	2101 Beneficial owner
Invesco Advisers, Inc.	2102 Investment manager
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Invesco Hong Kong Limited	2102 Investment manager
Invesco Corporate Class Inc.	2106 Person having a security interest in shares
M&g Plc	2201 Interest of corporation controlled by you
Shanghai Industrial Holdings Limited	2201 Interest of corporation controlled by you
Shanghai Industrial Investment (holdings) Company Limited	2201 Interest of corporation controlled by you
Serenity Investment Master Fund Limited	2101 Beneficial owner
Serenity Capital Management, Ltd.	2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd.	2201 Interest of corporation controlled by you
S.i. Infrastructure Holdings Limited	2201 Interest of corporation controlled by you

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines